AtriCureATRC -0.49%76 Interest Coverage is 0.39 as of Mar. 2026. GuruFocus rates ATRC with a GF Score™ of 76/100 and a GF Value™ of $39.73 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 468 Medical Devices & Instruments companies, AtriCure ranks worse than 213675% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. AtriCure's
Operating Income
for the
three
months ended in Mar. 2026 was $0.5 Mil. AtriCure's Interest Expense for the
three
months ended in Mar. 2026 was $-1.3 Mil.
AtriCure's interest coverage for the quarter that ended in Mar. 2026 was 0.39.
The higher the ratio, the stronger the company's financial strength is.
The historical rank and industry rank for AtriCure's Interest Coverage or its related term are showing as below:
ATRC's Interest Coverage is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 15.71 * Ranked among companies with meaningful Interest Coverage only.
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
AtriCure Interest Coverage Related Terms
AtriCure Interest Coverage Historical Data
* Premium members only.
The historical data trend for AtriCure's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
ATRC vs STAA, NNNN, KMTS: Interest Coverage Comparison
For the Medical Instruments & Supplies subindustry, AtriCure's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AtriCure Interest Coverage vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, AtriCure's Interest Coverage distribution charts can be found below:
* The bar in red indicates where AtriCure's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AtriCure (ATRC) has a Interest Coverage of 0.39 as of Mar. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on AtriCure and its competitors. According to the industry distribution chart, AtriCure ranks #999999 out of 468 companies in the Medical Devices & Instruments industry.
Is AtriCure's Interest Coverage too high?
AtriCure's current Interest Coverage is 0.39. The Medical Devices & Instruments industry median Interest Coverage is 15.71. AtriCure's value of 0.39 is 97.5% below this industry median. Based on the distribution chart, AtriCure ranks #999999 out of 468 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, AtriCure has a GF Score™ of 76/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does AtriCure's Interest Coverage compare to STAA and NNNN?
According to the Medical Devices & Instruments industry distribution chart, AtriCure ranks #999999 out of 468 companies for Interest Coverage. This places AtriCure in the lower half of its industry. The industry median Interest Coverage is 15.71. AtriCure's value of 0.39 is 97.5% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Medical Devices & Instruments company?
The median Interest Coverage among Medical Devices & Instruments companies is 15.71, based on 468 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. AtriCure's current Interest Coverage of 0.39 is 97.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on AtriCure and its competitors. For the Medical Devices & Instruments industry, the median Interest Coverage is 15.71 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AtriCure's current Interest Coverage is 0.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AtriCure stock overvalued right now?
Based on GuruFocus' analysis, AtriCure (ATRC) is currently considered Modestly Undervalued. The stock's GF Value™ is $39.73, compared to a current price of $28.30 — trading 28.8% below its estimated fair value. The current Interest Coverage is 0.39 and 97.5% below the Medical Devices & Instruments industry median of 15.71. AtriCure's overall GF Score™ is 76/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For AtriCure (ATRC), the current Interest Coverage is 0.39 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is AtriCure (ATRC) Overvalued in 2026?
Based on GuruFocus' analysis, AtriCure stock appears to be undervalued.
The current stock price of $28.30 is trading 28.8% below its estimated GF Value™ of $39.73.
GuruFocus considers AtriCure to be Modestly Undervalued.
Key valuation signals for ATRC:
Interest Coverage: 0.39
GF Value™: $39.73 vs. price of $28.30 (28.8% below fair value)
Industry Position: 97.5% below the Medical Devices & Instruments median (#999999 of 468)
No single metric tells the full story. See the ATRC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation, Pacing and Sensing, and others. Geographically, it generates a majority of its revenue from the United States. Cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures.
76GF Score
Get the complete analysis for ATRC
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ATRC has been successfully added to your 
